TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Xspray Pharma AB ( (SE:XSPRAY) ) has issued an announcement.
Xspray Pharma has submitted a New Drug Application to the FDA for XS003, an improved formulation of nilotinib for chronic myeloid leukemia, showcasing superior bioequivalence and reduced food interaction compared to the reference drug. This submission marks a significant step in Xspray’s strategy to capture a share of the USD 2.7 billion U.S. market for protein kinase inhibitors, potentially offering better treatment outcomes and adherence for patients.
More about Xspray Pharma AB
Xspray Pharma AB is a pharmaceutical company focused on developing improved versions of marketed protein kinase inhibitors (PKIs) using its innovative HyNap™ technology. The company aims to lead the market in enhanced PKIs for cancer treatment, with a portfolio that includes candidates like Dasynoc®, XS003-nilotinib, and others.
Average Trading Volume: 36,157
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.55B
Find detailed analytics on XSPRAY stock on TipRanks’ Stock Analysis page.